Delivery of the p38 MAPkinase Inhibitor SB202190 to Angiogenic Endothelial Cells: Development of Novel RGD-Equipped and PEGylated Drug−Albumin Conjugates Using Platinum(II)-Based Drug Linker Technology
Kai Temming(University of Groningen), Robbert J. Kok(Utrecht University), Paul van der Hoeven, Eli Dijkers(University Medical Center Groningen), Grietje Molema(University Medical Center Groningen), M. Lacombe(Université du Québec à Rimouski), Klaas Poelstra(University of Groningen), László Őrfi, Jai Prakash(Radboud University Nijmegen), Teresa Gonzalo(University of Groningen), Gÿorgý Kéri(Semmelweis University)
Cited by 46
Related Papers
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Diverse origins of the myofibroblast—implications for kidney fibrosis
|Nature Reviews Nephrology|2015|305
Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges
|International Journal of Pharmaceutics|2016|285